Harikrishna Makani1, Sripal Bangalore2, Azhar Supariwala1, Jorge Romero3, Edgar Argulian1, Franz H Messerli4. 1. Division of Cardiology, St Luke's Roosevelt Hospital, Columbia University College of Physicians and Surgeons, 1000, 10th Avenue, Suite 3B-30, New York, NY 10019, USA. 2. New York University School of Medicine, New York, NY, USA. 3. Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, USA. 4. Division of Cardiology, St Luke's Roosevelt Hospital, Columbia University College of Physicians and Surgeons, 1000, 10th Avenue, Suite 3B-30, New York, NY 10019, USA messerli.f@gmail.com.
Abstract
AIMS: Angiotensin receptor blockers (ARBs) are available in different dosages and it is common clinical practice to uptitrate if blood pressure goal is not achieved with the initial dose. Data on the incremental antihypertensive efficacy with uptitration are scarce. It is also unclear if antihypertensive efficacy of losartan is comparable with other ARBs. METHODS AND RESULTS: We systematically reviewed PubMed/EMBASE/Cochrane databases for all randomized clinical trials until December 2012 reporting 24 h ambulatory blood pressure (ABP) for most commonly available ARBs in patients with hypertension. Reduction in ABP with ARBs was evaluated at 25% of the maximum (max) dose, 50% of the max dose, and at the max dose. Comparison was made between 24 h BP-lowering effect of losartan 50 and 100 mg and other ARBs at 50% max dose and the max dose, respectively. Sixty-two studies enrolling 15 289 patients (mean age 56 years; 60% men) with a mean duration of 10 weeks were included in the analysis. Overall, the dose-response curve with ARBs was shallow with decrease of 10.3/6.7 (systolic/diastolic), 11.7/7.6, and 13.0/8.3 mmHg with 25% max dose, 50% max dose, and with the max dose of ARBs, respectively. Losartan in the dose of 50 mg lowered ABP less well than other ARBs at 50% max dose by 2.5 mmHg systolic (P < 0.0001) and 1.8 mmHg diastolic (P = 0.0003). Losartan 100 mg lowered ABP less well than other ARBs at max dose by 3.9 mm Hg systolic (P = 0.0002) and 2.2 mmHg diastolic (P = 0.002). CONCLUSION: In this comprehensive analysis of the antihypertensive efficacy of ARBs by 24 h ABP, we observed a shallow dose-response curve, and uptitration marginally enhanced the antihypertensive efficacy. Blood pressure reduction with losartan at starting dose and at max dose was consistently inferior to the other ARBs. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Angiotensin receptor blockers (ARBs) are available in different dosages and it is common clinical practice to uptitrate if blood pressure goal is not achieved with the initial dose. Data on the incremental antihypertensive efficacy with uptitration are scarce. It is also unclear if antihypertensive efficacy of losartan is comparable with other ARBs. METHODS AND RESULTS: We systematically reviewed PubMed/EMBASE/Cochrane databases for all randomized clinical trials until December 2012 reporting 24 h ambulatory blood pressure (ABP) for most commonly available ARBs in patients with hypertension. Reduction in ABP with ARBs was evaluated at 25% of the maximum (max) dose, 50% of the max dose, and at the max dose. Comparison was made between 24 h BP-lowering effect of losartan 50 and 100 mg and other ARBs at 50% max dose and the max dose, respectively. Sixty-two studies enrolling 15 289 patients (mean age 56 years; 60% men) with a mean duration of 10 weeks were included in the analysis. Overall, the dose-response curve with ARBs was shallow with decrease of 10.3/6.7 (systolic/diastolic), 11.7/7.6, and 13.0/8.3 mmHg with 25% max dose, 50% max dose, and with the max dose of ARBs, respectively. Losartan in the dose of 50 mg lowered ABP less well than other ARBs at 50% max dose by 2.5 mmHg systolic (P < 0.0001) and 1.8 mmHg diastolic (P = 0.0003). Losartan 100 mg lowered ABP less well than other ARBs at max dose by 3.9 mm Hg systolic (P = 0.0002) and 2.2 mmHg diastolic (P = 0.002). CONCLUSION: In this comprehensive analysis of the antihypertensive efficacy of ARBs by 24 h ABP, we observed a shallow dose-response curve, and uptitration marginally enhanced the antihypertensive efficacy. Blood pressure reduction with losartan at starting dose and at max dose was consistently inferior to the other ARBs. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Domenico Galzerano; Paolo Tammaro; Luca del Viscovo; Diana Lama; Antonio Galzerano; Roberto Breglio; Bernardino Tuccillo; Giuseppe Paolisso; Paolo Capogrosso Journal: Am J Hypertens Date: 2005-12 Impact factor: 2.689
Authors: George Bakris; Dominic Sica; Venkata Ram; Timothy Fagan; Paul T Vaitkus; Robert J Anders Journal: Am J Hypertens Date: 2002-01 Impact factor: 2.689
Authors: Matthew R Weir; Henry A Punzi; John M Flack; Kathy A Stoakes; Kathleen J Chavanu; Wei Li; Robert Dubiel Journal: Postgrad Med Date: 2011-01 Impact factor: 3.840
Authors: David H G Smith; Maarten-Jan M Cramer; Joel M Neutel; Rohan Hettiarachchi; Stephen Koval Journal: Blood Press Monit Date: 2003-06 Impact factor: 1.444
Authors: Chun Lin Chen; Daksha Desai-Krieger; Stephan Ortiz; Majid Kerolous; Harold M Wright; Parviz Ghahramani Journal: Am J Ther Date: 2015 Sep-Oct Impact factor: 2.688
Authors: James C Moon; Brian Godman; Max Petzold; Samantha Alvarez-Madrazo; Kathleen Bennett; Iain Bishop; Anna Bucsics; Ulrik Hesse; Andrew Martin; Steven Simoens; Corinne Zara; Rickard E Malmström Journal: Front Pharmacol Date: 2014-10-08 Impact factor: 5.810